Ameriprise
CTMX icon

Ameriprise’s CytomX Therapeutics CTMX Stock Holding History

Ameriprise’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$306K Sell
65,015
-164,584
-72% -$835K ﹤0.01% 3755
2025
Q4 		$989K Buy
229,599
+71,270
+45% +$271K ﹤0.01% 3345
2025
Q3 		$505K Buy
+158,329
New +$357K ﹤0.01% 3620
2022
Q4 		– Sell
-74,853
Closed -$109K – 3979
2022
Q3 		$109K Buy
+74,853
New +$115K ﹤0.01% 3812
2018
Q3 		– Sell
-51,852
Closed -$1.19M – 3733
2018
Q2 		$1.19M Sell
51,852
-941
-2% -$24K ﹤0.01% 2953
2018
Q1 		$1.5M Buy
+52,793
New +$1.51M ﹤0.01% 2802

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return